Veloxis’ management group simply needed more commercial strength to get US sales of its drug product Envarsus up and running. That was the relatively simple conclusion the company’s Board of Directors had reached and the reason why it said last week that CEO Bill Polvino would resign with immediate effect to make way for Craig Collard, says Chairman Mette Kirstine Agger.
“We are now launching Envarsus in the US, meaning we have a biotech company that goes from being a development company in the classic biotech sense to becoming a commercial company with its own commercialization in the US. When we bring in Craig Collard now, it’s because Craig has solid commercial and strategic experience with gearing up for a launch, carrying it out, and building a company from there. Bigger pharma outfits have the organization to launch, but in a small biotech company it’s something you have to build. Craig has been commercial his whole life and it’s where he has his strengths,” Metter Kirstine Agger tells MedWatch, adding: